| Document |
Document Title |
|
WO/2023/122616A1 |
Aspects of the present disclosure provide methods for the chemical synthesis of cytidine-5'-monophospho-N-glycyl-sialic acid (GSC).
|
|
WO/2023/121483A1 |
The present application is directed to immunomodulatory compositions comprising invariant NKT cell (iNKT cell) agonist compounds that induce expansion of tissue resident memory T-cells (Trm Cells) in combination with an immune stimulator...
|
|
WO/2023/109273A1 |
A method for preparing islatravir, comprising: 1) subjecting a compound of formula II, serving as a raw material, to a selective hydroxyl protection reaction to generate a compound of formula III; 2) subjecting the compound of formula II...
|
|
WO/2023/113038A1 |
As an oligonucleotide solid-phase synthesis method which makes it possible to cut out a synthesized oligonucleotide even under mild conditions, disclosed is, for example, an oligonucleotide solid-phase synthesis method which comprises a ...
|
|
WO/2023/111683A1 |
Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.
|
|
WO/2023/104039A1 |
The present invention relates to the field of medicines, and specifically relates to a ribofuranosyl pyridine derivative, and a pharmaceutical composition thereof and a use thereof. The present invention provides a compound as shown in f...
|
|
WO/2023/103306A1 |
The present invention relates to a method for preparing deuterated cytidine derivative 25. The method has mild reaction routes and conditions, a high conversion rate and selectivity, a high reaction yield and reaction efficiency, low ene...
|
|
WO/2023/106963A1 |
The invention relates to the fields of medicine, pharmacology and the chemical and pharmaceutical industry, and more particularly to a novel crystalline form V of [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimi
din-1-yl]oxol...
|
|
WO/2023/106964A1 |
The invention relates to the fields of medicine, pharmacology and the chemical and pharmaceutical industry, and more particularly to a novel crystalline form IV of [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimi
din-1-yl]oxo...
|
|
WO/2023/107673A2 |
Disclosed herein, inter alia, are methods and cleavable compounds that minimize byproduct formation following cleavage.
|
|
WO/2023/099471A1 |
Provided herein is a method of producing a polynucleotide or an analogue or derivative thereof, comprising providing a support-attached nucleoside, nucleotide, polynucleotide or derivative or analogue thereof, which is a compound of form...
|
|
WO/2023/097308A1 |
Embodiments of the present application relate to the preparation of 2'-O-protected nucleoside phosphoramidites and conjugation of the 2'-O-protected nucleoside to a solid support. More specifically, the present application relates to nuc...
|
|
WO/2023/093722A1 |
The present application relates to a compound having a structure shown in formula (I), wherein n1 is an integer selected from 4-21, and n2 is an integer selected from 1-2. The present invention also relates to a composition, comprising a...
|
|
WO/2023/023513A9 |
Provided herein are stable, modified oligonucleotides comprising a 5'-alkyl phosphate or derivatives thereof and methods for preparing the same.
|
|
WO/2023/097291A1 |
Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of Complement Factor B (CFB). In certain aspects, the compounds, compositions, and methods of the disclosure can be used to ...
|
|
WO/2023/089617A1 |
The present invention relates to conjugates comprising amino-acid-cytarabine, in particular, conjugates of cytarabine and two or more amino acids selected from alanine, aspartic acid, glutamic acid, asparagine, or glutamine for use in th...
|
|
WO/2023/086557A1 |
Disclosed are compounds and compositions to the treatment of infectious diseases and methods of treating such diseases. The compounds and compositions include derivatives of clevudine. The compounds and compositions include derivatives o...
|
|
WO/2023/083295A1 |
The present disclosure relates to ester derivatives of N 4-hydroxycytidine (NHC), to pharmaceutical compositions comprising thereof, to the preparation method thereof, and to the use and method of the ester derivatives of N 4-hydroxycyti...
|
|
WO/2023/085242A1 |
The present invention provides an antiviral agent that comprises a compound represented by general formula (A-1) or (A-2) [wherein: R1 represent O, S, Se or =N-RO11; R2 represents O, S, Se or =N-OR11; R3 represents -O-R12, -S-R13 or a gu...
|
|
WO/2023/077503A1 |
A method for increasing the bulk density of a crystal of nicotinamide mononucleotide (NMN), and a crystal of NMN. The method comprises: dissolving NMN in water to obtain an aqueous solution of NMN; subjecting the aqueous solution of NMN ...
|
|
WO/2023/081105A1 |
Provided herein are cyclic phosphoramidate compounds, their preparation and their uses, such as treating liver or non-liver diseases or conditions.
|
|
WO/2023/080253A1 |
The present invention provides a method for producing mixed crystals of 5'-disodium guanylate (G) and 5'-disodium inosinate (I), the method including a first crystallization step for forming mixed crystals including G and I in an I/G rat...
|
|
WO/2023/076687A1 |
Provided herein are compositions, devices, systems and methods for DNA oligomer synthesis. Further provided are devices comprising addressable electrodes controlling polynucleotide synthesis (deprotection, extension, or cleavage, etc.). ...
|
|
WO/2023/076392A1 |
The present disclosure is concerned with Clofarabine analogs for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, c...
|
|
WO/2023/074843A1 |
[Problem] The problem of the present invention is to provide: a novel oligosaccharide that can be used in order to manufacture a 2-branched glycan having an α2,6-sialic acid structure at a non-reducing end; a method for manufacturing th...
|
|
WO/2023/071293A1 |
Disclosed in the present application is a method for preparing molnupiravir, which belongs to the technical field of drug preparation. The preparation method comprises the following steps: (1) adding the compound of formula (I) to an alc...
|
|
WO/2023/070010A1 |
The aspects of this disclosure relate to luminescently labeled nucleic acid nanostructure as well as methods and compositions for the detection and/or sequencing of one or more target molecules derived from a sample. The invention may ut...
|
|
WO/2023/069495A1 |
The present disclosure relates generally to 2'-geminal substituted nucleosides and nucleotides, and oligonucleotides and dsRNA molecules comprising such 2'-geminal substituted nucleosides and nucleotides.
|
|
WO/2023/069599A1 |
Embodiments of the present application relate to porous polymeric beads solid support for use in oligonucleotide synthesis and the method of producing and using the same. Further embodiments relate to porous polymeric beads and method fo...
|
|
WO/2023/065683A1 |
Disclosed are a novel deuterated purine nucleoside compound as shown in formula I, or a pharmaceutically acceptable salt, an isomer, or a prodrug thereof. Also disclosed are a preparation method for said deuterated compound, a compositio...
|
|
WO/2023/063168A1 |
The present invention addresses the problem of providing a composition useful for controlling pests. Disclosed is a pest controlling composition comprising a compound represented by formula (1) (in the formula: R1 and R2 independently re...
|
|
WO/2023/061319A1 |
Disclosed is a series of tricyclic heterocyclic derivatives. Specifically disclosed are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/054708A1 |
[Problem] To provide a novel method for producing a 2'-carbamoylalkyl-modified nucleoside having a pyrimidine base. [Solution] Provided are: a method for producing a 2'-carbamoylalkyl-modified uridine compound, characterized in that an a...
|
|
WO/2023/053039A1 |
Provided herein are novel compounds having an inhibitory effect on the activation of a STING pathway. The provided compounds are 1,2-diaminobenzimidazole derivatives represented by a compound formula (I) or a pharmaceutically acceptable ...
|
|
WO/2023/051675A1 |
The invention concerns compounds of Formula (X) which modulate, especially agonize alpha kinase 1 (ALPK1) and are useful for treating a condition, disease or disorder in which a decrease or increase in ALPK1 activity contributes to the p...
|
|
WO/2023/052468A1 |
The present application relates to novel nucleoside analogues of formula (I) and compositions containing said nucleoside analogues. Moreover, the present application provides processes for the preparation of the disclosed compounds, as w...
|
|
WO/2023/052970A1 |
Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer, or salt thereof, wherein R1, R2, R3, R4, R5, L1a, L1b, L2, L3, L4, L5, L6, L7, M1, M2, q, w, m ...
|
|
WO/2023/047141A1 |
Provided herein are analogues of S-adenosyl-L-methionine, methods of their preparation, and complexes and kits comprising the analogues. Said analogues find use in modifying, labelling and analysing a target molecule such as a nucleic acid.
|
|
WO/2023/049258A1 |
The present disclosure provides to linker compounds of Formula (I) or (II): pharmaceutically acceptable salts thereof, and related scaffolds and conjugates. More specifically, compounds of formula (l-A) are disclosed. The present disclos...
|
|
WO/2023/041786A1 |
The invention provides novel 5 -Fluorouracil derivatives that are useful as prodrugs for cancer treatment. 5 -Fluorouracil nucleoside triphosphates are masked at the terminal phosphate of the triphosphate group with residues that are cle...
|
|
WO/2023/039005A2 |
Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.
|
|
WO/2023/034617A1 |
The present invention is directed to new methods for the treatment of an infection by a virus from the genus Flavivirus, particularly Dengue fever virus, Yellow Fever virus, Zika virus, and West Nile virus, in a host in need thereof, typ...
|
|
WO/2023/031481A1 |
The present invention relates to a method for preparing cyclic guanosine-3', 5'- monophosphate analogues. The invention also relates to the new cyclic guanosine-monophosphate analogues and intermediates obtained by the method.
|
|
WO/2023/033481A1 |
The present invention relates to an adenosine diphosphate-ribose (ADP-ribose) binding peptide having anticancer activity and, more particularly, to an ADP-ribose binding peptide of a specific amino acid sequence, a modified product there...
|
|
WO/2023/027178A1 |
The present invention relates to a method for producing a cytidine-5'-diphosphate compound, the method comprising: (1) a step in which a solution containing a cytidine-5'-diphosphate compound is brought into contact with a basic ion exch...
|
|
WO/2023/026449A1 |
The purpose of the present invention is to provide a method for producing a cytidine 5'-diphosphate compound, in which cytidine 5'-phosphate can be efficiently separated from a crude cytidine 5'-diphosphate compound to concentrate the cy...
|
|
WO/2023/027065A1 |
The present invention provides a novel method for producing a 2'-modified guanosine compound represented by the formula. In the formula, R1 and R2 may be the same or different, and each represents a hydrogen atom, an optionally substitut...
|
|
WO/2023/023550A1 |
The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linkage. In some embod...
|
|
WO/2023/021286A2 |
The present invention relates to novel nucleotide complexes which enhance the enzymatic production of DNA. The nucleotide complexes includes a divalent cation at a ratio of 0.2-1.5 divalent cations per nucleotide, whilst monovalent ions ...
|
|
WO/2023/019670A1 |
A purification method for fluorescein-labeled nucleoside triphosphate, specifically comprising: purifying a fluorescein-labeled nucleoside triphosphate crude product by means of liquid chromatography, and collecting a target fraction, wh...
|
